Showing 1,621 - 1,640 results of 4,368 for search '(( significant decrease decrease ) OR ( significant clinical decrease ))~', query time: 0.48s Refine Results
  1. 1621
  2. 1622
  3. 1623

    Image 4_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

    Published 2025
    “…Four patients had no significant clinical changes. Six patients experienced marked improvement. …”
  4. 1624

    Image 2_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

    Published 2025
    “…Four patients had no significant clinical changes. Six patients experienced marked improvement. …”
  5. 1625

    Image 3_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

    Published 2025
    “…Four patients had no significant clinical changes. Six patients experienced marked improvement. …”
  6. 1626

    Table 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.xlsx by Øystein Fluge (200378)

    Published 2025
    “…Four patients had no significant clinical changes. Six patients experienced marked improvement. …”
  7. 1627

    Image 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

    Published 2025
    “…Four patients had no significant clinical changes. Six patients experienced marked improvement. …”
  8. 1628
  9. 1629
  10. 1630
  11. 1631
  12. 1632
  13. 1633
  14. 1634
  15. 1635
  16. 1636
  17. 1637
  18. 1638

    Table1_Astragaloside IV Alleviates Tacrolimus-Induced Chronic Nephrotoxicity via p62-Keap1-Nrf2 Pathway.DOCX by Ping Gao (172038)

    Published 2025
    “…However, there are no drugs available in the clinic to relieve it at present. Astragaloside IV (AS-IV) is a saponin extract of the Astragalus which is widely used in the treatment of kidney disease. …”
  19. 1639

    Table1_Astragaloside IV Alleviates Tacrolimus-Induced Chronic Nephrotoxicity via p62-Keap1-Nrf2 Pathway.DOCX by Ping Gao (172038)

    Published 2025
    “…However, there are no drugs available in the clinic to relieve it at present. Astragaloside IV (AS-IV) is a saponin extract of the Astragalus which is widely used in the treatment of kidney disease. …”
  20. 1640

    Image1_Comprehensive analysis of Hibisci mutabilis Folium extract’s mechanisms in alleviating UV-induced skin photoaging through enhanced network pharmacology and experimental vali... by Wenyuan Chen (1770583)

    Published 2024
    “…In vitro experiments showed that EHMF significantly reduced UV-induced inflammatory factors in HaCaT cells and improved cell survival rates. …”